Abstract
Work in our laboratory over the last 10 years has shown that prolonged brain calpain-2 activation following a variety of insults plays a critical role in brain pathology resulting from these insults, including neuronal damage, brain inflammation, and cognitive impairment. My laboratory is collaborating with NeurAegis, Inc, to develop selective calpain-2 inhibitors for the treatment of a number of neurological disorders, including traumatic brain injury and concussions. We have identified a lead clinical candidate, NA-184, which significantly inhibits neuronal damage in rodent models of TBI, as well as a blood biomarker, P13BP, which reflects brain calpain-2 activation. We will discuss our plans to bring NA-184 to the clinic in 2024.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
